Le Lézard
Classified in: Health
Subject: FDA

Alpha Tau Receives Breakthrough Device Designation from the FDA for Alpha DaRTtm

Alpha Tau Medical

JERUSALEM, June 8, 2021 /PRNewswire/ -- Alpha Tau Medical, the developer of the pioneering alpha-radiation cancer therapy Alpha DaRT,TM is pleased to announce that it has received a Breakthrough Device Designation for Alpha DaRT from the U.S. Food and Drug Administration (FDA). This designation applies to the treatment of Squamous Cell Carcinoma of the skin and oral cavity without curative standard of care.

"The FDA's recognition of the Alpha DaRT as a Breakthrough Device is a tremendous milestone for the company, as we seek to bring our revolutionary technology to patients in need," said Alpha Tau CEO Uzi Sofer. "This confirms our long-standing hopes and expectations for this product, and comes at the perfect time to accelerate our clinical trial program that is moving ahead rapidly now in the U.S."

Alpha Tau Chief Medical Officer Dr. Robert Den added, "This achievement was the result of the dedication and hard work of the entire Alpha Tau team. While we are motivated by our mission to help every patient possible, it is exciting and gratifying to see external recognition of our vision of clinical excellence."

Breakthrough Device is a category designed by the FDA to expedite the review process and to facilitate the clinical trial development of devices that treat life-threatening conditions. The designation is awarded when a device's preliminary clinical data suggest it might be more effective than the current standard of care on clinically significant endpoints of efficacy, safety, or patient quality of life.  In addition, to speed access to essential new medical technologies, a Medicare coverage pathway called Medicare Coverage of Innovative Technology stands to provide FDA Breakthrough Devices with Medicare coverage for 4 years following FDA marketing authorization.

Alpha Tau submitted data to the FDA supporting this designation, including a pilot clinical study of Alpha DaRT treatment of SCC of the skin, head and neck, in which almost 80% of the lesions showed a complete response, and 100% demonstrated a partial or complete response, alongside a mild safety profile.

In preclinical studies using Alpha DaRT, a response was observed in all tested solid tumors, including pancreatic, lung, breast, and prostate tumor cells. These cancers and others will be investigated as part of the Alpha DaRT clinical trial program, which includes a skin cancer feasibility trial currently ongoing at Memorial Sloan Kettering Cancer Center in New York and other sites across the U.S.

About Alpha Tau Medical, Ltd.

Founded in 2016, Alpha Tau Medical Ltd, is an Israeli oncology therapeutics company that focuses on research, development, and commercialization of the Alpha DaRTtm technology for the treatment of solid tumors.  

Alpha DaRTtm(Diffusing Alpha-emitters Radiation Therapy) is an innovative technology that enables the highly potent and uniquely conformal alpha-irradiation of solid tumors. The treatment is delivered by intratumoral insertion of Radium-224, which allows for the release and diffusion of alpha-emitting radioisotopes, releasing alpha particles that can destroy the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT mainly affects the tumor, and can spare the healthy tissue around it. 

Amnon Gat
Tel: +1 833-455-3278

Media Package: https://www.dropbox.com/sh/4wtkdggbyatxyly/AACobJHTz_OD2dNE3Z0cYKc1a?dl=0

SOURCE Alpha Tau Medical

These press releases may also interest you

at 06:05
Merck , known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that the European Medicines Agency (EMA) has initiated a rolling review for molnupiravir, an investigational oral antiviral medicine, for the...

at 06:02
Following the successful and well-received Allograft line, Neoss is excited to announce the addition of NeoGenix XPtm this autumn to our existing product portfolio. NeoGenix XPtm is a safe and clinically proven natural bone substitute, that closer...

at 06:00
Being vaccinated during childhood with the BCG (Bacille Calmette-Guérin) vaccine against tuberculosis is not a long-term protective factor against COVID-19, despite what was thought at the beginning of the pandemic. A team of scientists from the...

at 06:00
The healthcare artificial intelligence (AI) market is expected to surpass USD 34.5 billion by 2027, as reported in a research study by Global Market Insights Inc. Artificial intelligence has revolutionized the field of healthcare by designing...

at 06:00
The light therapy market size is set to grow by USD 201.87 million from 2021 to 2025, according to Technavio. The report offers a detailed analysis of the market in optimistic, probable, and pessimistic forecast scenarios....

at 06:00
10x Genomics , a life sciences leader focused on mastering biology to advance human health, today marked a major Asia Pacific (APAC) expansion with the grand opening celebration of its Singapore manufacturing facility and commercial hub. The...

News published on 8 june 2021 at 12:18 and distributed by: